

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 295/08, 211/14, 401/04, A61K 31/445, 31/495	A1	(11) International Publication Number: WO 97/41108 (43) International Publication Date: 6 November 1997 (06.11.97)
(21) International Application Number: PCT/US97/05777 (22) International Filing Date: 8 April 1997 (08.04.97) (30) Priority Data: 60/016,513 30 April 1996 (30.04.96) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GLASE, Shelly, Ann [US/US]; 4468 Hillside Court, Ann Arbor, MI 48105 (US). PURCHASE, Terri, Stoeber [US/US]; 4961 Ravine Court, Ann Arbor, MI 48105 (US). WISE, Lawrence, David [US/US]; 1241 Barrister, Ann Arbor, MI 48105 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SUBSTITUTED PIPERAZINES AND PIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS (57) Abstract Substituted piperazines and piperidines and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as dopamine antagonists and antipsychotic agents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

SUBSTITUTED PIPERAZINES AND PIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS

BACKGROUND OF THE INVENTION

The present invention relates to novel substituted piperazines and piperidines and derivatives thereof useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment. The novel compounds of the present invention are central nervous system agents. More particularly, the novel compounds of the present invention are dopamine antagonists.


Dopamine (DA) D2 antagonists are established as antipsychotic agents. Undesired consequences of DA D2 antagonism are extrapyramidal side effects and tardive dyskinesia. More recently, the DA D4 receptor has been identified as having a possible role in schizophrenia. The atypical antipsychotic drug clozapine has a tenfold higher affinity for the DA D4 receptor than the D2 (Van Tol H.H.J., Bunzow J.R., Guan H.-C., et al., "Cloning of a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine." Nature, 1991;350:614-619) and is notable for its lack of extrapyramidal side effects and tardive dyskinesia. The levels of mRNA for the D4 receptor are much higher in the frontal cortex and limbic region, which are associated with cognitive and emotional function, than in the striatum, which is associated with movement (Van Tol, et al., supra, 1991). In addition, Seeman P., Guan H.-C., and Van Tol H.H.M., "Dopamine D4 receptors elevated in schizophrenia," Nature, 1993;365:441-445 has reported a sixfold increase of the

-2-

D4 receptor number in postmortem specimens from patients with schizophrenia compared to controls.

The compounds of the present invention were shown to selectively bind to the DA D4 receptor while having weak affinity for the DA D2 and DA D3 receptors.

A series of piperazines represented by the Formula I




I

A = CO, COCH₂, COCH₂CH₂, CH(OH)CH₂CH₂, COCH₂CH₂CH₂, or CH(OH)CH₂CH₂CH₂

R = CH₃, 2-(2'-hydroxyethoxy)ethyl, cyclohexyl, benzyl, *m*-methyl-, or *p*-*t*-butylbenzyl, phenethyl, C₆H₅, *o*- or *p*-chlorophenyl, *o*-, *m*-, or *p*-methoxyphenyl, *o*-, *m*-, or *p*-tolyl, 2,6-xylyl, 2-pyridyl, 2-pyrimidyl, or 2-thiazolyl are disclosed by Petigara R.B., et al., Journal of Medicinal Chemistry, 1968;11:332-336 as central nervous system depressants.

A series of arylpiperazines represented by the Formula I



I

wherein R is hydrogen, trifluoromethyl, hydroxy, nitro, halogen, lower alkyl, or lower alkoxy;

R' is hydrogen, trifluoromethyl, halogen, lower alkyl, or lower alkoxy; and


-3-

R" is hydrogen or lower alkoxy; or
two of R, R', and R" are lower alkylenedioxy; or an
acid addition salt thereof are disclosed in United
Kingdom Published Patent Application GB 2,057,441A as
having circulation-enhancing activity.

The compounds of the present invention, unlike the
compounds disclosed in Petigara R.B., et al., supra,
(1968) and United Kingdom Published Patent Application
GB 2,057,441A, interact selectively with the DA D4
receptor. Thus, the compounds of the present invention
are DA D4 selective antagonists which are useful in the
treatment of psychosis such as schizophrenia without
the extrapyramidal side effects associated with an
agent that interacts with the DA D2 receptor.

SUMMARY OF THE INVENTION

Accordingly, a first aspect of the present
invention is a compound of Formula I



wherein X is N or CH; and
R is aryl or heteroaryl; or a pharmaceutically
acceptable acid additional salt thereof;
with the proviso that when X is N and R is aryl, aryl
is not phenyl,


phenyl monosubstituted by

lower alkyl,
lower alkoxy,
halogen, or

-4-

nitro,
phenyl disubstituted by lower alkyl, or
phenyl trisubstituted by lower alkoxy.

5 A second aspect of the present invention is a
compound of Formula Ia



wherein X is N or CH; and

15 R is aryl or heteroaryl; or a pharmaceutically
acceptable acid addition salt thereof; with the
following provisos:

- (a) that when X is N or CH, and R is aryl, aryl
is not phenyl, or
20 phenyl monosubstituted by
lower alkyl,
lower alkoxy, or
halogen; and
(b) that when X is N and R is heteroaryl,
25 heteroaryl is not 2-, 3-, or 4-pyridinyl.

As dopamine antagonists, the compounds of
Formula I and Formula Ia are antipsychotic agents
useful for treating psychoses such as schizophrenia.

30 A still further embodiment of the present
invention is a pharmaceutical composition for
administering an effective amount of a compound of
Formula I or Formula Ia in unit dosage form in the
treatment methods mentioned above.

-5-

Finally, the present invention is directed to a method for production of a compound of Formula I or Formula Ia.

5

DETAILED DESCRIPTION OF THE INVENTION

In the compounds of Formula I or Formula Ia, the term "lower alkyl" means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.

The term "aryl" means an aromatic radical which is a phenyl group or phenyl group substituted by 1 to 4 substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, amino, or cyano, such as, for example, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4-methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2-methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl, and the like.

The term "heteroaryl" means a heteroaromatic radical which is 2-, 3- or 4-pyridinyl 4-, 5-, 6-, or 7-benzo[b]furanyl, 4-, 5-, 6-, or 7-benzo[b]thienyl, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl.

"Lower alkoxy" and "lower thioalkoxy" are O-alkyl or S-alkyl of from 1 to 6 carbon atoms as defined above for "lower alkyl."

-6-

"Halogen" is fluorine, chlorine, bromine, or iodine.

The term "host" means mammals which includes humans.

5 Pharmaceutically acceptable acid addition salts of the compounds of Formula I or Formula Ia include salts derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorous, and the like, as
10 well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include
15 sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate,
20 suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
25 Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19).

30 The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a
35 base and isolating the free base in the conventional manner. The free base forms differ from their

-7-

respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

5 Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be
10 encompassed within the scope of the present invention.

 A preferred compound of Formula I is one wherein R is phenyl,

 phenyl substituted by 1 to 3 substituents selected from the group consisting of:

15 lower alkyl,
 lower alkoxy,
 lower thioalkoxy,
 halogen,
 nitro,
20 amino, and
 cyano,
 2-, 3-, or 4-pyridinyl,
 4-, 5-, 6-, or 7-benzo[b]furanyl,
 4-, 5-, 6-, or 7-benzo[b]thienyl,
25 4-, 5-, 6-, or 7-indolyl,
 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, or
 2-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl; with
 the proviso that when X is N, R is not phenyl,
 phenyl monosubstituted by
30 lower alkyl,
 lower alkoxy,
 halogen, or
 nitro,
 phenyl disubstituted by lower alkyl, or
35 phenyl trisubstituted by lower alkoxy.

-8-

A more preferred compound of Formula I is one wherein

R is phenyl,

phenyl substituted by 1 to 2 substituents selected
5 from the group consisting of:

lower alkyl,

lower alkoxy, and

halogen, or

2-pyridinyl; with the proviso that when X is N,

10 R is not phenyl,

phenyl monosubstituted by

lower alkyl,

lower alkoxy, or

halogen, or

15 phenyl disubstituted by lower alkyl.

A most preferred compound of Formula I is one wherein

R is phenyl,

20 phenyl substituted by 1 to 2 substituents selected
from the group consisting of:

methyl,

methoxy, and

chloro, or

25 2-pyridinyl; with the proviso that when X is N,

R is not phenyl,

phenyl monosubstituted by

methyl,

methoxy, and

30 chloro, or

phenyl disubstituted by methyl.

-9-

Particularly valuable compounds of Formula I are:

1-(2,5-dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;

5 1-(2,3-dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;

1-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;

1-(2,3-dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;

10 1-(3,4-dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;

1-(2-chloro-3-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

15 1-(2-chloro-4-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

1-(2-chloro-5-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

1-(3-chloro-2-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

20 1-(3-chloro-4-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

1-(5-chloro-2-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

25 1-(4-chloro-2-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

1-(4-chloro-3-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

1-pyridin-2-yl-4-(3,4,5-trimethoxybenzyl)-
piperazine; and

30 4-phenyl-1-(3,4,5-trimethoxybenzyl)piperidine; or
a pharmaceutically acceptable acid addition salt
thereof.

35 Furthermore, particularly valuable compounds of
Formula I used in the methods of the present invention
are:

-10-

- 1-phenyl-4-(3,4,5-trimethoxybenzyl)piperazine;
1-(2-chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(3-chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
5 piperazine;
1-(4-chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-*o*-tolyl-4-(3,4,5-trimethoxybenzyl)piperazine;
1-*m*-tolyl-4-(3,4,5-trimethoxybenzyl)piperazine;
10 1-*p*-tolyl-4-(3,4,5-trimethoxybenzyl)piperazine;
1-(2-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(3-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
15 1-(4-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(2,5-dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(2,3-dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
20 piperazine;
1-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(2,3-dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
25 1-(3,4-dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(2-chloro-3-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-(2-chloro-4-methylphenyl)-4-(3,4,5-trimethoxy-
30 benzyl)piperazine;
1-(2-chloro-5-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-(3-chloro-2-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
35 1-(3-chloro-4-methylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

-11-

1-(5-chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;

1-(4-chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;

5 1-(4-chloro-3-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;

1-pyridin-2-yl-4-(3,4,5-trimethoxybenzyl)-piperazine; and

10 4-phenyl-1-(3,4,5-trimethoxybenzyl)piperidine; or a pharmaceutically acceptable acid addition salt thereof.

A preferred compound of Formula Ia is one wherein R is phenyl,

15 phenyl substituted by 1 to 3 substituents selected from the group consisting of:

lower alkyl,
lower alkoxy,
lower thioalkoxy,
20 halogen,
nitro,
amino, and
cyano,

25 2-, 3-, or 4-pyridinyl,
4-, 5-, 6-, or 7-benzo[b]furanyl,
4-, 5-, 6-, or 7-benzo[b]thienyl,
4-, 5-, 6-, or 7-indolyl,
2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, or
2-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl; with
30 the following provisos:

(a) that when X is N or CH, R is not phenyl, or phenyl monosubstituted by

lower alkyl,
lower alkoxy, or
35 halogen, and

-12-

- (b) that when X is N, R is not 2-, 3-, or 4-pyridinyl.

5 A more preferred compound of Formula Ia is one wherein
R is phenyl,
phenyl substituted by 1 to 2 substituents selected from the group consisting of:
lower alkyl,
10 lower alkoxy, and
halogen, or
2-pyridinyl; with the following provisos:
(a) that when X is N or CH, R is not phenyl,
phenyl monosubstituted by
15 lower alkyl,
lower alkoxy, or
halogen, and
(b) that when X is N, R is not 2-pyridinyl.

20 A most preferred compound of Formula Ia is one wherein
R is phenyl,
phenyl substituted by 1 to 2 substituents selected from the group consisting of:
25 methyl,
methoxy, and
chloro, or
2-pyridinyl; with the following provisos:
(a) that when X is N or CH, R is not phenyl,
30 phenyl monosubstituted by
methyl,
methoxy, and
chloro, and
(b) that when X is N, R is not 2-pyridinyl.

35

-13-

Particularly valuable compounds of Formula Ia are:

1-(2-chloro-3-methylphenyl)-4-(2,3-dimethoxy-benzyl)piperazine;

5 1-(2-chloro-3-methylphenyl)-4-(2,4-dimethoxy-benzyl)piperazine;

1-(2-chloro-3-methylphenyl)-4-(2,5-dimethoxy-benzyl)piperazine; and

10 1-(2-chloro-3-methylphenyl)-4-(3,4-dimethoxy-benzyl)piperazine; or a pharmaceutically acceptable acid addition salt thereof.

Furthermore, particularly valuable compounds of Formula Ia used in the methods of the present invention are:

15 1-(2-chloro-3-methylphenyl)-4-(2,3-dimethoxy-benzyl)piperazine;

1-(2-chloro-3-methylphenyl)-4-(2,4-dimethoxy-benzyl)piperazine;

20 1-(2-chloro-3-methylphenyl)-4-(2,5-dimethoxy-benzyl)piperazine; and

1-(2-chloro-3-methylphenyl)-4-(3,4-dimethoxy-benzyl)piperazine; or a pharmaceutically acceptable acid addition salt thereof.

25 The compounds of Formula I and Formula Ia are valuable dopamine antagonists. The tests employed indicate that compounds of Formula I and Formula Ia possess dopamine antagonist activity.

30 Compounds were tested for their ability to bind to dopamine receptors as measured by their inhibition of [³H]spiperone binding to the human D2, D3 receptors in a receptor assay described by MacKenzie R.G., VanLeeuwen D., Pugsley T.A., et al., "Characterization of the human dopamine D3 receptor expressed in
35 transfected cell lines." Eur. J. Pharmacol.-Mol. Pharmacol., 1994;266:79-85; for the human D4 dopamine

-14-

receptor in a receptor assay by Pugsley T.A., Davis M.D., Akunne H.C., et al., "CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical Effects." J. Pharmacol. Exp. Ther., 1995;274:898-911; and for ability to block the action of an agonist in a [³H]thymidine incorporation assay described by Lajiness N.E., Chio C.L., Huff R.M., "D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations." J. Pharmacol. Exp. Ther., 1993;267:1573-81. This test determines the agonist/antagonist character of a compound by measuring [³H]thymidine uptake in Chinese hamster ovary (CHO) pro-5 cells expressing the DA D4 receptor. Agonists, such as quinpirole, promote cell growth and subsequent [³H]thymidine incorporation, while antagonists block the action of agonists. Compounds of the present invention were shown to be antagonists by blocking the action of quinpirole. The above test methods are incorporated herein by reference.

The binding data in the table below shows the dopamine antagonist activity of representative compounds of Formula I and Formula Ia.

25


Biological Activity of Compounds of Formula I and Formula Ia

Example	Compound	DA D4 Ki (nM)	DA D3 Ki (nM)	DA D2 Ki (nM)
1	1-phenyl-4-(3,4,5-trimethoxybenzyl)piperazine	6.2	1505	1022
7	1- <i>m</i> -tolyl-4-(3,4,5-trimethoxybenzyl)piperazine, monohydrochloride	8.6	2766	1456
5	1- <i>p</i> -tolyl-4-(3,4,5-trimethoxybenzyl)piperazine, monohydrochloride	7.5	6818	1415
19	1-(3-chloro-2-methylphenyl)-4-(3,4,5-trimethoxy- benzyl)piperazine, monohydrochloride	6.1	2118	1055
20	1-(3-chloro-4-methylphenyl)-4-(3,4,5-trimethoxy- benzyl)piperazine, monohydrochloride	4.5	2025	3290
21	1-(5-chloro-2-methylphenyl)-4-(3,4,5-trimethoxy- benzyl)piperazine, monohydrochloride	6.5	3515	1565
26	1-(2-chloro-3-methylphenyl)-4-(2,3-dimethoxy- benzyl)piperazine, monohydrochloride	12.7	2646	2895
27	1-(2-chloro-3-methylphenyl)-4-(2,4-dimethoxy- benzyl)piperazine	4.4	409	762
28	1-(2-chloro-3-methylphenyl)-4-(2,5-dimethoxy- benzyl)piperazine	11.3	730	2084
29	1-(2-chloro-3-methylphenyl)-4-(3,4-dimethoxy- benzyl)piperazine, monohydrochloride	5.0	1207	2342
10				

-16-

A compound of Formula I

5




I

wherein X is N or CH; and

10

R is aryl or heteroaryl; or a pharmaceutically acceptable acid addition salt thereof may be prepared by reacting a compound of Formula II

15



II


20

wherein X and R are as defined above in the presence of a metal hydride such as, for example, aluminum hydride and the like in a solvent such as, for example, tetrahydrofuran and the like at about -10°C to about room temperature for about 10 minutes to about 24 hours to afford a compound of Formula I. Preferably, the reaction is carried out in the presence of aluminum hydride in tetrahydrofuran at about 0°C for about 2 hours.

25

30

A compound of Formula II is prepared from a compound of Formula III




III

35

-17-

wherein X and R are as defined above and 3,4,5-tri-methoxybenzoyl chloride in the presence of a base such as, for example, triethylamine and the like and a solvent such as, for example, dichloromethane and the like at about room temperature for about 1 hour to about 24 hours to afford a compound of Formula II. Preferably, the reaction is carried out in the presence of triethylamine in dichloromethane at about room temperature for about 2 hours.


A compound of Formula Ia



Ia

wherein X is N or CH; and

R is aryl or heteroaryl; or a pharmaceutically acceptable acid addition salt thereof may be prepared by reacting a compound of Formula IIa




IIa

wherein X and R are as defined above using the methodology described for preparing a compound of Formula I from a compound of Formula II to afford a compound of Formula Ia.

A compound of Formula IIa is prepared from a compound of Formula III and a compound of Formula IV

-18-



IV

5 using the methodology described for preparing a compound of Formula II from a compound of Formula III and 3,4,5-trimethoxybenzoyl chloride to afford a compound of Formula IIa.

10 Compounds of Formula III and Formula IV are either known or capable of being prepared by methods known in the art.

The compounds of the present invention can be prepared and administered in a wide variety of oral and
15 parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or Formula Ia or a corresponding pharmaceutically acceptable salt of a compound of Formula I
20 or Formula Ia.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets,
25 pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating
30 agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the
35 carrier having the necessary binding properties in

-19-

suitable proportions and compacted in the shape and size desired.

5 The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is
10 intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly,
15 cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

 For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa
20 butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

25 Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

30 Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

35 Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or

-20-

synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which
5 are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors,
10 stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is
15 subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or
20 ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 1 mg to
25 1000 mg preferably 10 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as antipsychotic agents, the
30 compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 1 mg to about 50 mg per kilogram daily. A daily dose range of about 5 mg to about 25 mg per kilogram is preferred. The dosages, however, may be varied
35 depending upon the requirements of the patient, the severity of the condition being treated, and the

-21-

compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.

EXAMPLE 1

1-(2-Chloro-3-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-piperazine

Step A: Preparation of [4-(2-chloro-3-methylphenyl)-piperazine-1-yl]-(3,4,5-trimethoxyphenyl)methanone

3,4,5-Trimethoxybenzoyl chloride (2.03 g, 8.8 mmol) in dichloromethane (10 mL) is added dropwise to a solution of 2-chloro-3-methylphenyl piperazine (1.98 g, 8.0 mmol) and triethylamine (4.5 mL, 32.0 mmol) in dichloromethane (90 mL) and stirred for 2 hours at room temperature. The reaction mixture is washed with water, dried (magnesium sulfate), and concentrated in vacuo. The resulting solid is purified by medium pressure liquid chromatography (MPLC) on silica gel eluting with 40% ethyl acetate/hexane to give 2.52 g of the title compound as a white solid; mp 156-159°C.

Step B: Preparation of 1-(2-chloro-3-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine

A solution of aluminum chloride (0.279 g, 2.09 mmol) in anhydrous diethyl ether (20 mL) is added

-22-

dropwise to a suspension of lithium aluminum hydride (0.238 g, 6.27 mmol) in anhydrous tetrahydrofuran (20 mL) at 0°C and stirred for 0.5 hour. To this mixture is added dropwise a solution of [4-(2-chloro-
5 3-methylphenyl)piperazine-1-yl]-(3,4,5-trimethoxy-phenyl)methanone (2.12 g, 5.23 mmol) in anhydrous tetrahydrofuran (20 mL). The suspension is stirred for 2 hours at 0°C, followed by dropwise addition of 2N sodium hydroxide. The mixture is filtered through
10 Celite and concentrated in vacuo. The resulting product is purified by MPLC on silica gel eluting with 40% ethyl acetate/hexane to give 1.74 g of the title compound as a white solid; mp 112-113°C.

15 In a process analogous to Example 1 using appropriate starting materials, the corresponding compounds of Formula I (Examples 2-29) are prepared as follows:

20 EXAMPLE 2

1-Phenyl-4-(3,4,5-trimethoxybenzyl)piperazine, monohydrochloride; mp 270°C.

EXAMPLE 3

25 1-(2-Chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-piperazine, monohydrochloride; mp 234-235°C.

EXAMPLE 4

30 1-(3-Chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-piperazine, monohydrochloride; mp 252°C (dec).

EXAMPLE 5

1-(4-Chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-piperazine; mp 72-75°C

35

-23-

EXAMPLE 6

1-o-Tolyl-4-(3,4,5-trimethoxybenzyl)piperazine,
monohydrochloride; mp 216-219°C.

5

EXAMPLE 7

1-m-Tolyl-4-(3,4,5-trimethoxybenzyl)piperazine,
monohydrochloride; mp 260°C (dec).

EXAMPLE 8

10

1-p-Tolyl-4-(3,4,5-trimethoxybenzyl)piperazine,
monohydrochloride; mp 267°C (dec).

EXAMPLE 9

15

1-(2-Methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 231°C.

EXAMPLE 10

20

1-(3-Methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 242-244°C (dec).

EXAMPLE 11

1-(4-Methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 267°C (dec).

25

EXAMPLE 12

1-(2,5-Dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 247°C (dec).

EXAMPLE 13

30

1-(2,3-Dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine; mp 126-129°C.

EXAMPLE 14

35

1-(3,4-Dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine; mp 136-139°C.

-24-

EXAMPLE 15

1-(2,3-Dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 231-234°C (dec).

5

EXAMPLE 16

1-(3,4-Dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine; mp 82-84°C.

EXAMPLE 17

10

1-(2-Chloro-4-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 216-218°C.

EXAMPLE 18

15

1-(2-Chloro-5-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 230°C.

EXAMPLE 19

20

1-(3-Chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 225-227°C.

EXAMPLE 20

1-(3-Chloro-4-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 220°C.

25

EXAMPLE 21

1-(5-Chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 199-202°C.

EXAMPLE 22

30

1-(4-Chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 175-178°C.

EXAMPLE 23

35

1-(4-Chloro-3-methylphenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine, monohydrochloride; mp 251-253°C.

-25-

EXAMPLE 24

1-Pyridin-2-yl-4-(3,4,5-trimethoxybenzyl)piperazine,
monohydrochloride; mp 262-265°C.

5

EXAMPLE 25

4-Phenyl-1-(3,4,5-trimethoxybenzyl)piperidine,
monohydrochloride; mp 230°C.

EXAMPLE 26

10 1-(2-Chloro-3-methylphenyl)-4-(2,3-dimethoxybenzyl)-
piperazine, monohydrochloride; mp 183-185°C.

EXAMPLE 27

15 1-(2-Chloro-3-methylphenyl)-4-(2,4-dimethoxybenzyl)-
piperazine, monohydrochloride; mp 103-106°C.

EXAMPLE 28

20 1-(2-Chloro-3-methylphenyl)-4-(2,5-dimethoxybenzyl)-
piperazine, monohydrochloride; mp 115-119°C.


EXAMPLE 29

1-(2-Chloro-3-methylphenyl)-4-(3,4-dimethoxybenzyl)-
piperazine, monohydrochloride; mp 193-196°C.

-26-

CLAIMS

1. A compound of Formula I



I

wherein X is N or CH; and

R is aryl or heteroaryl; or a
pharmaceutically acceptable acid addition
salt thereof; with the proviso that when X is
N and R is aryl, aryl is not phenyl,
phenyl monosubstituted by
lower alkyl,
lower alkoxy,
halogen, or
nitro,
phenyl disubstituted by lower alkyl, or
phenyl trisubstituted by lower alkoxy.

2. A compound according to Claim 1, in which

R is phenyl,
phenyl substituted by 1 to
3 substituents selected from the group
consisting of:
lower alkyl,
lower alkoxy,
lower thioalkoxy,
halogen,
nitro,
amino, and
cyano,
2-, 3-, or 4-pyridinyl,

-27-

15 4-, 5-, 6-, or 7-benzo[b]furanyl,
4-, 5-, 6-, or 7-benzo[b]thienyl,
4-, 5-, 6-, or 7-indolyl,
2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl,
or
20 2-, 3-, 4-, 5-, 6-, 7-, or
8-isoquinolinyl.

3. A compound according to Claim 2, in which
R is phenyl
phenyl substituted by 1 to
2 substituents selected from the group
5 consisting of:
lower alkyl,
lower alkoxy, and
halogen, or
2-pyridinyl.

4. A compound according to Claim 3, in which
R is phenyl,
phenyl substituted by 1 to
2 substituents selected from the group
5 consisting of:
methyl,
methoxy, and
chloro, or
2-pyridinyl.


5. A compound according to Claim 4 selected from the
group consisting of:

1-(2,5-dichlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
5 1-(2,3-dichlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

-28-

- 10 1-(2,3-dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-(3,4-dimethylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-(2-chloro-3-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 15 1-(2-chloro-4-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-(2-chloro-5-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 20 1-(3-chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-(3-chloro-4-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-(5-chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 25 1-(4-chloro-2-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-(4-chloro-3-methylphenyl)-4-(3,4,5-trimethoxybenzyl)piperazine;
 1-pyridin-2-yl-4-(3,4,5-trimethoxybenzyl)-
 30 piperazine; and
 4-phenyl-1-(3,4,5-trimethoxybenzyl)-piperidine.

6. A compound of Formula Ia



wherein X is N or CH; and
 R is aryl or heteroaryl; or a pharmaceutically acceptable acid addition salt thereof; with the
 10 following provisos:

-29-

- (a) that when X is N or CH, and R is aryl,
aryl is not phenyl, or
phenyl monosubstituted by
lower alkyl,
lower alkoxy, or
halogen, and
- (b) that when X is N and R is heteroaryl,
heteroaryl is not 2-, 3-, or
4-pyridinyl.

7. A compound according to Claim 6, in which
R is phenyl,
phenyl substituted by 1 to 3 substituents
selected from the group consisting of:
- lower alkyl,
lower alkoxy,
lower thioalkoxy,
halogen,
nitro,
amino, and
cyano,
- 2-, 3-, or 4-pyridinyl,
4-, 5-, 6-, or 7-benzo[b]furanyl,
4-, 5-, 6-, or 7-benzo[b]thienyl,
4-, 5-, 6-, or 7-indolyl,
2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, or
2-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl.

8. A compound according to Claim 7, in which
R is phenyl,

-30-

phenyl substituted by 1 to 2 substituents
selected from the group consisting of:

- 5 lower alkyl,
 lower alkoxy, and
 halogen, or
2-pyridinyl.

9. A compound according to Claim 8, in which
 R is phenyl,

phenyl substituted by 1 to 2 substituents
selected from the group consisting of:

- 5 methyl,
 methoxy, and
 chloro, or
2-pyridinyl.

10. A compound according to Claim 9 selected from the
 group consisting of:

1-(2-chloro-3-methylphenyl)-4-(2,3-dimethoxy-
benzyl)piperazine;


- 5 1-(2-chloro-3-methylphenyl)-4-(2,4-dimethoxy-
benzyl)piperazine;

1-(2-chloro-3-methylphenyl)-4-(2,5-dimethoxy-
benzyl)piperazine; and

- 10 1-(2-chloro-3-methylphenyl)-4-(3,4-dimethoxy-
benzyl)piperazine.

11. A method of treating psychoses comprising
 administering to a host suffering therefrom a
 therapeutically effective amount of a compound of
 Formula I

5



I

-31-

10

wherein X is N or CH; and

R is aryl or heteroaryl; or a
pharmaceutically acceptable acid addition salt
thereof.

12. The method of Claim 11 wherein a compound of
Formula I is selected from the group consisting
of:

- 5 1-phenyl-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(2-chlorophenyl)-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(3-chlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
10 1-(4-chlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-o-tolyl-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-m-tolyl-4-(3,4,5-trimethoxybenzyl)-
15 piperazine;
1-p-tolyl-4-(3,4,5-trimethoxybenzyl)-
piperazine;
1-(2-methoxyphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
20 1-(3-methoxyphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-(4-methoxyphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-(2,5-dichlorophenyl)-4-(3,4,5-trimethoxy-
25 benzyl)piperazine;
1-(2,3-dichlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
1-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;

-32-


- 30 1-(2,3-dimethylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
 1-(3,4-dimethylphenyl)-4-(3,4,5-trimethoxy-
benzyl)piperazine;
 1-(2-chloro-3-methylphenyl)-4-(3,4,5-tri-
35 methoxybenzyl)piperazine;
 1-(2-chloro-4-methylphenyl)-4-(3,4,5-tri-
methoxybenzyl)piperazine;
 1-(2-chloro-5-methylphenyl)-4-(3,4,5-tri-
methoxybenzyl)piperazine;
40 1-(3-chloro-2-methylphenyl)-4-(3,4,5-tri-
methoxybenzyl)piperazine;
 1-(3-chloro-4-methylphenyl)-4-(3,4,5-tri-
methoxybenzyl)piperazine;
 1-(5-chloro-2-methylphenyl)-4-(3,4,5-tri-
45 methoxybenzyl)piperazine;
 1-(4-chloro-2-methylphenyl)-4-(3,4,5-tri-
methoxybenzyl)piperazine;
 1-(4-chloro-3-methylphenyl)-4-(3,4,5-tri-
methoxybenzyl)piperazine;
50 1-pyridin-2-yl-4-(3,4,5-trimethoxybenzyl)-
piperazine; and
 4-phenyl-1-(3,4,5-trimethoxybenzyl)-
piperidine.

13. The method of Claim 11 wherein the psychosis is schizophrenia.
14. The method of Claim 12 wherein the psychosis is schizophrenia.
15. A pharmaceutical composition comprising a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

-33-

16. A pharmaceutical composition adjusted for administration as an agent for treating schizophrenia comprising a therapeutically effective amount of a compound according to Claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

17. A method of treating psychoses comprising administering to a host suffering therefrom a therapeutically effective amount of a compound of Formula Ia



Ia

wherein X is N or CH; and

R is aryl or heteroaryl; or a pharmaceutically acceptable acid addition salt thereof.

18. The method of Claim 17 wherein a compound of Formula I is selected from the group consisting of:

1-(2-chloro-3-methylphenyl)-4-(2,3-dimethoxybenzyl)piperazine;


1-(2-chloro-3-methylphenyl)-4-(2,4-dimethoxybenzyl)piperazine;

1-(2-chloro-3-methylphenyl)-4-(2,5-dimethoxybenzyl)piperazine; and

1-(2-chloro-3-methylphenyl)-4-(3,4-dimethoxybenzyl)piperazine.

-34-


19. The method of Claim 17 wherein the psychosis is schizophrenia.
20. The method of Claim 18 wherein the psychosis is schizophrenia.
21. A pharmaceutical composition comprising a compound according to Claim 6 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
22. A pharmaceutical composition adjusted for administration as an agent for treating schizophrenia comprising a therapeutically effective amount of a compound according to Claim 6 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
23. A method of preparing a compound of Formula I



I

wherein X is N or CH; and

R is aryl or heteroaryl; or a pharmaceutically acceptable acid addition salt thereof comprising reacting a compound of Formula II




II


-35-

20 wherein X and R are as defined above in the
presence of a metal hydride in a solvent to afford
a compound of Formula I; and if desired,
converting a compound of Formula I to a
corresponding pharmaceutically acceptable acid
addition salt by conventional means and, if so
25 desired, converting the corresponding
pharmaceutically acceptable acid addition salt to
a compound of Formula I by conventional means.

24. A method of preparing a compound of Formula Ia



10 wherein X is N or CH; and
R is aryl or heteroaryl; or a
pharmaceutically acceptable acid addition salt
thereof comprising reacting a compound of
Formula IIa



20 wherein X and R are as defined above in the
presence of a metal hydride in a solvent to afford
a compound of Formula Ia; and if desired,
converting a compound of Formula Ia to a
corresponding pharmaceutically acceptable acid
25 addition salt by conventional means and, if so

-36-

desired, converting the corresponding
pharmaceutically acceptable acid addition salt to
a compound of Formula Ia by conventional means.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/05777

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D295/08 C07D211/14 C07D401/04 A61K31/445 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 177 392 A (INNOTHERA) 9 April 1986 see page 5, compound 17; claims 1, 5 ---	1,15
X	GB 2 057 441 A (MERZ & CO.) 1 April 1981 cited in the application see claims 1,36; examples 7,16,18 ---	1,15
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 11, 1968, pages 332-336, XP000590800 R. B. PETIGARA ET AL.: "Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives. I" cited in the application see table I --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

29 July 1997

Date of mailing of the international search report

0 8. 08. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/US 97/05777

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 390 654 A (MITSUBISHI KASEI CORP.) 3 October 1990 see claims 1, 21; table 1, compounds 66, 68 ---	6,21
X	EP 0 385 351 A (NISSHIN FLOUR MILLING CO., LTD.) 5 September 1990 see claims 1, 13; table 3, compound 11 ---	6,21
A,P	WO 96 22977 A (SUNTORY LTD.) 1 August 1996 see abstract; page 83, compound 29; page 87, compound 46; page 89, compound 56 ---	1,6,15, 21
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 11, no. 6, November 1968, pages 1144-1150, XP002036253 R. N. PRASAD ET AL.: "Potential Antihypertensive Agents. II. Unsymmetrically 1,4-Disubstituted Piperazines. I" see table V, compound 100 ---	6
A	ARZNEIMITTEL-FORSCHUNG, vol. 17, no. 9, 1967, pages 1145-1149, XP002036254 J. GOOTJES ET AL.: "Synthesis and Pharmacology of a Number of seco Analogues of 2-(p-Chlorophenyl)-1,3,4,6,7,11b-hexa- hydro-9,10-dimethoxy-2H-benzo[a]- quinolizine" see table 6, compound 45 ---	6
A	EP 0 007 067 A (CIBA-GEIGY AG) 23 January 1980 see claims 1,7 ---	6
A	EP 0 624 584 A (DAIICHI PHARMACEUTICAL CO., LTD.) 17 November 1994 see claim 1; page 59, compound 103 -----	6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/05777

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 177392 A	09-04-86	FR 2573075 A JP 61178966 A US 4673675 A	16-05-86 11-08-86 16-06-87
GB 2057441 A	01-04-81	DE 2934450 A DE 2934488 A AT 376965 B AT 375075 B AU 538005 B AU 6171980 A CA 1153377 A CH 643549 A FR 2463768 A NL 8004783 A SE 8005943 A US 4370329 A US 4370330 A BE 884918 A JP 56034676 A	26-03-81 26-03-81 25-01-85 25-06-84 26-07-84 05-03-81 06-09-83 15-06-84 27-02-81 27-02-81 26-02-81 25-01-83 25-01-83 16-12-80 06-04-81
EP 390654 A	03-10-90	JP 3007263 A JP 6086438 B AT 113940 T DE 69013959 D DE 69013959 T ES 2063300 T CA 2013037 A US 5053409 A	14-01-91 02-11-94 15-11-94 15-12-94 16-03-95 01-01-95 27-09-90 01-10-91
EP 385351 A	05-09-90	JP 2229162 A CA 2011144 A DE 69015842 D DE 69015842 T US 5025012 A	11-09-90 01-09-90 23-02-95 18-05-95 18-06-91
WO 9622977 A	01-08-96	AU 4459596 A CA 2185984 A EP 0755923 A	14-08-96 01-08-96 29-01-97
EP 7067 A	23-01-80	JP 55011592 A	26-01-80

INTERNATIONAL SEARCH REPORT

1. International application No.

PCT/US 97/05777

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 11-14, 17-20
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

...information on patent family members

Inter nal Application No

PCT/US 97/05777

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 624584 A	17-11-94	AU 677644 B	01-05-97
		AU 6309694 A	17-11-94
		CA 2123548 A	15-11-94
		CN 1101039 A	05-04-95
		FI 942252 A	15-11-94
		JP 7097364 A	11-04-95
		NO 941802 A	15-11-94
